Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle

被引：33

作者：

Gerratana, Lorenzo ^{[1
,2
]}

Bonotto, Marta ^{[1
,2
]}

Bozza, Claudia ^{[1
,2
]}

Ongaro, Elena ^{[1
,2
]}

Fanotto, Valentina ^{[1
,2
]}

Pelizzari, Giacomo ^{[1
,2
]}

Puglisi, Fabio ^{[1
,2
]}

机构：

[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy

[2] Univ Hosp Udine, Dept Oncol, Piazzale SM Misericordia, I-33100 Udine, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2017年 / 17卷 / 03期

关键词：

Anti-HER2; pertuzumab; HER2 positive breast cancer; clinical trials; EPIDERMAL-GROWTH-FACTOR; TRASTUZUMAB PLUS DOCETAXEL; 1ST FDA APPROVAL; OPEN-LABEL; NEOADJUVANT PERTUZUMAB; ADJUVANT TRASTUZUMAB; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; AMERICAN SOCIETY; PHASE-III;

D O I：

10.1080/14712598.2017.1282944

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Introduction: The mechanism of action of pertuzumab, a recombinant anti-HER2 humanized monoclonal antibody, is complementary to trastuzumab's. On 8 June 2012, the Food and Drug Administration approved the combination of pertuzumab with trastuzumab and docetaxel as first-line treatment of HER2-positive metastatic breast cancer. Furthermore, pertuzumab is the first drug to be approved in the neoadjuvant setting using a pathological complete response as an endpoint.Areas covered: The review provides insights into the main mechanisms of action of pertuzumab. In addition, it gives complete coverage of the landmark clinical and translational trials for this agent.Expert opinion: The new therapeutic algorithm in the treatment of HER2-positive advanced disease and the awaited results of the Aphinity trial are expected to impact the sequence of anti-HER2 treatment. Accordingly, the value of pertuzumab beyond progression needs to be properly studied. Furthermore, to improve the toxicity profile and efficacy of future treatment, new pertuzumab-based regimens are being investigated.

引用

页码：365 / 374

页数：10

共 52 条

[1]

New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available [J].

Abramson, Vandana ;

Arteaga, Carlos L. .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :952-958

[2]

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer [J].

Agus, DB ;

Gordon, MS ;

Taylor, C ;

Natale, RB ;

Karlan, B ;

Mendelson, DS ;

Press, MF ;

Allison, DE ;

Sliwkowski, MX ;

Lieberman, G ;

Kelsey, SM ;

Fyfe, G .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2534-2543

[3]

First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer [J].

Amiri-Kordestani, Laleh ;

Wedam, Suparna ;

Zhang, Lijun ;

Tang, Shenghui ;

Tilley, Amy ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2014, 20 (21) :5359-5364

[4]

Treatment of HER2-positive breast cancer: current status and future perspectives [J].

Arteaga, Carlos L. ;

Sliwkowski, Mark X. ;

Osborne, C. Kent ;

Perez, Edith A. ;

Puglisi, Fabio ;

Gianni, Luca .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) :16-32

[5]

First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE [J].

Bachelot, Thomas Denis ;

Ciruelos, Eva ;

Peretz-Yablonski, Tamar ;

Puglisi, Fabio ;

Schneeweiss, Andreas ;

Campone, Mario ;

Coudert, Bruno P. ;

Kaufman, Bella ;

Wardley, Andrew M. ;

Bastiere-Truchot, Lydie ;

Freudensprung, Ulrich ;

Restuccia, Eleonora ;

Miles, David .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[6]

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Im, Seock-Ah ;

Clark, Emma ;

Ross, Graham ;

Kiermaier, Astrid ;

Swain, Sandra M. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3753-+

[7]

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[8]

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [J].

Baselga, Jose ;

Gelmon, Karen A. ;

Verma, Shailendra ;

Wardley, Andrew ;

Conte, PierFranco ;

Miles, David ;

Bianchi, Giulia ;

Cortes, Javier ;

McNally, Virginia A. ;

Ross, Graham A. ;

Fumoleau, Pierre ;

Gianni, Luca .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1138-1144

[9]

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial [J].

Bianchini, G. ;

Pusztai, L. ;

Pienkowski, T. ;

Im, Y. -H. ;

Bianchi, G. V. ;

Tseng, L. -M. ;

Liu, M. -C. ;

Lluch, A. ;

Galeota, E. ;

Magazzu, D. ;

de la Haba-Rodriguez, J. ;

Oh, D. -Y. ;

Poirier, B. ;

Pedrini, J. L. ;

Semiglazov, V. ;

Valagussa, P. ;

Gianni, L. .

ANNALS OF ONCOLOGY, 2015, 26 (12) :2429-2436

[10]

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer [J].

Blumenthal, Gideon M. ;

Scher, Nancy S. ;

Cortazar, Patricia ;

Chattopadhyay, Somesh ;

Tang, Shenghui ;

Song, Pengfei ;

Liu, Qi ;

Ringgold, Kimberly ;

Pilaro, Anne M. ;

Tilley, Amy ;

King, Kathryn E. ;

Graham, Laurie ;

Rellahan, Barbara L. ;

Weinberg, Wendy C. ;

Chi, Bo ;

Thomas, Colleen ;

Hughes, Patricia ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2013, 19 (18) :4911-4916

← 1 2 3 4 5 6 →